“Bristol-Myers Squibb is to share intellectual property rights on an important HIV/AIDS drug in a patent pool designed to make treatments more widely available in poor countries,” Reuters reports. The licensing deal between the Medicines Patent Pool (MPP) and Bristol “will enable generic drug firms around the world to produce affordable versions of atazanavir, [sold] under the brand name Reyataz, and to combine it with other medicines to make treatment easier,” the news agency notes (Hirschler, 12/12). “This is the MPP’s first agreement covering a [WHO]-preferred second-line therapy. The WHO estimates there will be over one million people on second-line treatment by 2016, and many more will need access to these therapies,” according to an MPP press release (12/12).